1. Academic Validation
  2. Cyclophilin C Participates in the US2-Mediated Degradation of Major Histocompatibility Complex Class I Molecules

Cyclophilin C Participates in the US2-Mediated Degradation of Major Histocompatibility Complex Class I Molecules

  • PLoS One. 2015 Dec 21;10(12):e0145458. doi: 10.1371/journal.pone.0145458.
Daniel C Chapman 1 Pawel Stocki 2 David B Williams 1 2
Affiliations

Affiliations

  • 1 Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • 2 Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Abstract

Human cytomegalovirus uses a variety of mechanisms to evade immune recognition through major histocompatibility complex class I molecules. One mechanism mediated by the immunoevasin protein US2 causes rapid disposal of newly synthesized class I molecules by the endoplasmic reticulum-associated degradation pathway. Although several components of this degradation pathway have been identified, there are still questions concerning how US2 targets class I molecules for degradation. In this study we identify Cyclophilin C, a peptidyl prolyl isomerase of the endoplasmic reticulum, as a component of US2-mediated immune evasion. Cyclophilin C could be co-isolated with US2 and with the class I molecule HLA-A2. Furthermore, it was required at a particular expression level since depletion or overexpression of Cyclophilin C impaired the degradation of class I molecules. To better characterize the involvement of Cyclophilin C in class I degradation, we used LC-MS/MS to detect US2-interacting proteins that were influenced by Cyclophilin C expression levels. We identified malectin, PDIA6, and TMEM33 as proteins that increased in association with US2 upon Cyclophilin C knockdown. In subsequent validation all were shown to play a functional role in US2 degradation of class I molecules. This was specific to US2 rather than general ER-associated degradation since depletion of these proteins did not impede the degradation of a misfolded substrate, the null Hong Kong variant of α1-antitrypsin.

Figures